




Searching News Database: sarcoma
HSMN NewsFeed - 14 Nov 2023
FDA Clears Sirius Pintuition(R) for Long-term and Soft Tissue Implantation
FDA Clears Sirius Pintuition(R) for Long-term and Soft Tissue Implantation
HSMN NewsFeed - 7 Sep 2023
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
HSMN NewsFeed - 7 Feb 2019
Onkos Surgical(R) Announces the Release of MyTray(TM) a Breakthrough in Personalized Surgical Planning
Onkos Surgical(R) Announces the Release of MyTray(TM) a Breakthrough in Personalized Surgical Planning
HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
HSMN NewsFeed - 16 Oct 2018
Precision For Medicine Acquires Liquid Biopsy And Tissue Profiling Pioneer ApoCell
Precision For Medicine Acquires Liquid Biopsy And Tissue Profiling Pioneer ApoCell
HSMN NewsFeed - 24 Aug 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
HSMN NewsFeed - 3 May 2018
CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
HSMN NewsFeed - 30 Nov 2017
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
HSMN NewsFeed - 2 Aug 2017
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
HSMN NewsFeed - 13 Jul 2017
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
HSMN NewsFeed - 19 Dec 2016
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
HSMN NewsFeed - 11 Nov 2016
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
HSMN NewsFeed - 12 Sep 2016
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
HSMN NewsFeed - 19 Oct 2015
Virttu Biologics Announces Appointment Of Deirdre Y. Gillespie As Chief Executive Officer
Virttu Biologics Announces Appointment Of Deirdre Y. Gillespie As Chief Executive Officer
HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
HSMN NewsFeed - 31 Jul 2013
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
HSMN NewsFeed - 22 Jan 2013
Clinical Trials Advancing Proton Therapy Research Open at the CDH Proton Center, A ProCure Center
Clinical Trials Advancing Proton Therapy Research Open at the CDH Proton Center, A ProCure Center
HSMN NewsFeed - 29 Oct 2012
Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection
Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection
HSMN NewsFeed - 25 Apr 2012
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
HSMN NewsFeed - 17 Feb 2012
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer
HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
HSMN NewsFeed - 17 Mar 2011
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
HSMN NewsFeed - 16 Mar 2011
First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital
First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital
HSMN NewsFeed - 19 Jan 2011
First Patients Complete Proton Therapy Treatment at CDH Proton Center, A ProCure Center
First Patients Complete Proton Therapy Treatment at CDH Proton Center, A ProCure Center
HSMN NewsFeed - 8 Nov 2010
ZIOPHARM Oncology Appoints Brian L. Hamilton, M.D., Ph.D., as Senior Vice President, Clinical Operations
ZIOPHARM Oncology Appoints Brian L. Hamilton, M.D., Ph.D., as Senior Vice President, Clinical Operations
HSMN NewsFeed - 23 Jun 2010
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
HSMN NewsFeed - 6 Apr 2010
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
HSMN NewsFeed - 18 Feb 2010
BSD Medical Announces First Swiss Installation of the BSD-2000/3D Hyperthermia System at Kantonsspital Aarau
BSD Medical Announces First Swiss Installation of the BSD-2000/3D Hyperthermia System at Kantonsspital Aarau
HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
HSMN NewsFeed - 15 Oct 2009
Institute Curie Hospital Purchases Second TomoTherapy(R) Radiation Therapy System
Institute Curie Hospital Purchases Second TomoTherapy(R) Radiation Therapy System
HSMN NewsFeed - 29 Jun 2009
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 23 Sep 2008
BSD Medical Corp. Announces ESMO Recommends Hyperthermia as 'Standard Therapy' for Soft Tissue Sarcoma
BSD Medical Corp. Announces ESMO Recommends Hyperthermia as 'Standard Therapy' for Soft Tissue Sarcoma
HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
HSMN NewsFeed - 31 Jul 2008
BSD Medical's Premier Cancer Treatment System Can Now Treat Children's Cancers
BSD Medical's Premier Cancer Treatment System Can Now Treat Children's Cancers
HSMN NewsFeed - 17 Jun 2008
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
HSMN NewsFeed - 5 Jun 2008
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
HSMN NewsFeed - 7 Apr 2008
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
HSMN NewsFeed - 4 Feb 2008
Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
HSMN NewsFeed - 3 Jan 2008
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
HSMN NewsFeed - 14 Nov 2007
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
HSMN NewsFeed - 24 Sep 2007
ARIAD Initiates Phase 3 'Succeed' Trial of Oral Deforolimus in Patients with Metastatic Sarcomas
ARIAD Initiates Phase 3 'Succeed' Trial of Oral Deforolimus in Patients with Metastatic Sarcomas
HSMN NewsFeed - 20 Sep 2007
ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
HSMN NewsFeed - 27 Aug 2007
IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
HSMN NewsFeed - 1 Aug 2007
Deforolimus Approved as Nonproprietary Name for AP23573 - ARIAD's Novel mTOR Inhibitor
Deforolimus Approved as Nonproprietary Name for AP23573 - ARIAD's Novel mTOR Inhibitor
HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
HSMN NewsFeed - 12 Apr 2007
Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team
Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team
HSMN NewsFeed - 26 Dec 2006
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
HSMN NewsFeed - 11 May 2006
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from Gilead Sciences
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from Gilead Sciences
Additional items found! 117

Members Archive contains
117 additional stories matching:
sarcoma
(Password required)
sarcoma
(Password required)